TW199161B - Improvements process for chemical reactions on camptothecin or analogs thereof - Google Patents

Improvements process for chemical reactions on camptothecin or analogs thereof Download PDF

Info

Publication number
TW199161B
TW199161B TW80109255A TW80109255A TW199161B TW 199161 B TW199161 B TW 199161B TW 80109255 A TW80109255 A TW 80109255A TW 80109255 A TW80109255 A TW 80109255A TW 199161 B TW199161 B TW 199161B
Authority
TW
Taiwan
Prior art keywords
acid
item
camptothecin
patent application
scope
Prior art date
Application number
TW80109255A
Other languages
Chinese (zh)
Inventor
E Wall Monroe
C Wani Mansukh
G Tele Chhagan
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Application granted granted Critical
Publication of TW199161B publication Critical patent/TW199161B/en

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A process for preparing a reduced camptothecin derivative in which a camptothecin substrate bearing a reducible substituent is hydrolyzed under alkaline conditions to open the lactone E ring and form a carboxylate salt. The carboxylate salt is reduced to form a reduced carboxylate salt which is then contacted with acid to reform the lactone E ring. This procedure results in substantially increased yields of camptothecin derivatives.

Description

199161 五、發明説明 本發明夕背景 太發昍夕領城 本發明關偽於一種改良程序,用以在具有喜樹龄構造 的化合物上進行反應者。更特別者,本發明關偽於一種程 序,用以容易地在水糸介質中進行化學反應同時增進喜樹 鹼化合物的産率者。 背晉:> 紂論 喜樹鹸是一種五環植物龄,最初是被Wall et al存 CamDto theca acuminata木材與樹皮中分離出來的(’ Μ . E . Wall, M. C. Wani, C. E. Cook, K.H. Palmer, A. T. McPhail and G. A. Sia, J. Am. Chem. Sot!. . 91: 388 ( 1 966))。母體喜樹鹼具有高度生物活性且對於核酸的生 合成顯示強抑制活性。喜樹鹼對於實驗移植的癌,例如小 鼠的白血病L-12 10或老鼠的Walker 256腫瘤等表現出強力 的抗腫瘤活性。 喜樹鹾的強力抗腫廇活性激起了製備喜樹鐄類似物的 相當大地合成興趣。製備喜樹鹼類似物的方法和各種喜樹 鹼類似物已掲示於,例如美國專利4,894,456, 4,604,463 ,4,545,880 , 4,473,690和 4,43 1,098 以及這些美國專利 所討論的參考文獻等之中。 喜樹驗和其許多類似物不僅在水中而且在大多數有機 溶劑中都具有非常有限的溶解度。因此之故,當其五元環 以形成之時,就很難在喜樹鹼分子上進行後缠反應。喜樹 鹾和其類似物的低溶解度需要使用大量的溶劑。這些大量 先 閲 讀 背 而 之 注 意· % 項 塡- % 木 裝 經濟部中央櫺準屈C3:工消伢合作社印虹 本紙张尺度逍用中a B家楳半(CNS)T4規格(210X297公救) 3 Λ (ί Π 6 99161 五、發明説明() 先 閱 背 而 之 意 事 項 填 % 本 頁 溶劑會造成問題,例如溶劑處理,溶劑回收,溶劑成本及 處理時化合物損失導致産物産率的減損等。産物喜樹鹼或 喜樹_類似物以及合成順序中的中間體等用結晶法或用層 析分離法予以純化都會因為需要異常大量的溶劑而受阻和 耗費昂貴和/或不可行。 综上所述,有一種需要持缠存在箸欲尋求可消除先前 技術程序需要大量溶劑的用法之新穎改良的製備和純化喜 樹鹼和喜樹驗類似物之方法。 太發明夕槪要 因此,本發明的一値目的為提出一種程序,用以製備 喜樹鹼和喜樹鹼類似物而沒有上面提及先前技術程序的缺 陷者。 本發明的另一目的為提出一種製備喜樹鹼和其類似物 之程序,可以不需要大量昂貴溶劑而以高産率製得産物喜 樹鹼化合物。 經濟部屮央梂準局KX工消费合作杜印製 這些和其他目的從下面所述本發明程序的詳細説明即 可明白,其中,喜樹鹼化合物的A, B, C或D環上加上能夠 在鹺性或中性條件下被還原的取代基,再予以水解而形成 水溶性含取代基的羧酸鹽。然後將該菝酸鹽上的可還原性 取代基在驗性或中性介質中還原而形成已還原的喜樹鹾鹽 。該水溶性己還原的喜樹鹼衍生物即可用管柱層析分離法 接著結晶法予以鈍化。最後與酸接觸再形成内酯E環,因 而形成一値新的,改質的喜樹鹼化合物。 鲛佳奮旆例之註細銳明 本紙張尺度边用中8困家標準(CNS)肀4規格(210X297公:«:) 4 Λ (i Η 6 ..五工^明説咐一^ ) 作為本發明程序基質的喜樹鹼化合物具有熟知的喜樹 龄骨架结構,含有環A-E且在A, B, C,或D環上另外含有 至少一値可在鹼性或中性條件下被還原的取代基(R)。該 基質可為喜樹齡本身,其中,A-D琛上的取代基為氫原子 。另外,該基質也可為具有可在龄性或中性條件下被還原 的非氳取代*之喜樹鹼化合物。 下面所示構造(式)及圖解1中的所有構造(式)代表具 有所示構造的任何和所有的喜樹齡化合物異構物。例如, 代表著喜樹鹼化合物E環中20-位置上可能的不同構型而 産生的喜樹齡化合物20 (S)和20(R)兩種對映異構物之構造 。本發明範圍也包含著因R取代基的構造和/或位置所産 生的所有異構物。 (請先閱請背而之注意事項#^¾木頁) 裝-199161 V. Description of the invention The background of the present invention Taifa tanxichengcheng The present invention is based on an improved procedure for carrying out a reaction on a compound with a tree-like structure. More specifically, the present invention is concerned with a procedure for easily performing a chemical reaction in a water medium while increasing the yield of camptothecin compounds. Back Jin: > On the hi tree is a five-ringed plant age, originally isolated by Wall et al CamDto theca acuminata wood and bark ('Μ. E. Wall, MC Wani, CE Cook, KH Palmer , AT McPhail and GA Sia, J. Am. Chem. Sot! .. 91: 388 (1 966)). The parent camptothecin is highly biologically active and shows strong inhibitory activity against nucleic acid biosynthesis. Camptothecin exhibits strong antitumor activity against experimentally transplanted cancers, such as leukemia L-12 10 in mice or Walker 256 tumors in mice. The potent anti-tumor activity of Camptotheca acuminata has stimulated considerable synthetic interest in the preparation of camptotheca analogs. Methods for preparing camptothecin analogues and various camptothecin analogues have been shown, for example, in U.S. Patent Nos. 4,894,456, 4,604,463, 4,545,880, 4,473,690 and 4,43 1,098 and references discussed in these U.S. patents. Camptotheca acuminata and many of its analogs have very limited solubility not only in water but also in most organic solvents. Therefore, when the five-membered ring is formed, it is difficult to perform the post-winding reaction on the camptothecin molecule. The low solubility of Camptotheca adriaticus and its analogues requires the use of large amounts of solvents. A lot of these are read first, and pay attention to it.% 堡 塡-% The Ministry of Wood Economy Ministry of Economic Affairs Central Standard C3: Industrial Consumers ’Cooperative Cooperative Printing Co., Ltd. Printed on this paper, the paper size is used in a. A B Jiayuban (CNS) T4 specification (210X297 public rescue ) 3 Λ (ί Π 6 99161 Fifth, the description of the invention () First read the contradictions and fill in%. Solvents on this page will cause problems, such as solvent treatment, solvent recovery, solvent cost, and compound loss during processing, resulting in a reduction in product yield Etc. Purification of the product camptothecin or camptothecin analogs and intermediates in the synthesis sequence by crystallization or chromatographic separation will be hindered and costly and / or infeasible due to the need for unusually large amounts of solvent. As mentioned above, there is a need to maintain a presence and seek a novel and improved method for preparing and purifying camptothecin and camptothecin analogues that can eliminate the use of large amounts of solvents in the prior art procedures. An object of the invention is to propose a procedure for preparing camptothecin and camptothecin analogues without the above-mentioned defects of the prior art procedures. A procedure for the preparation of camptothecin and its analogues can be used to produce the product camptothecin compound in high yields without the need for a large amount of expensive solvents. These and other purposes are produced by the KX Industrial and Consumer Cooperation Bureau of the Ministry of Economic Affairs It can be understood from the detailed description of the procedure of the present invention described below, in which the A, B, C or D ring of the camptothecin compound is added with a substituent that can be reduced under the neutral or neutral conditions, and then hydrolyzed The water-soluble substituent-containing carboxylic acid salt is formed. The reducible substituent on the salt is then reduced in a test or neutral medium to form a reduced camptothecin salt. Camptothecin derivatives can be deactivated by column chromatography followed by crystallization. Finally, contact with an acid to form the lactone E ring, thus forming a new, modified camptothecin compound. Note: The sharpness of this paper is based on the use of the 8-sleeper standard (CNS) 4 specifications (210X297: «:) 4 Λ (i Η 6 .. 五 工 ^ 明说 令 一 ^) as the program substrate of the present invention The camptothecin compound has a well-known framework structure of camptotheca age, containing Ring AE and additionally contain at least one substituent (R) that can be reduced under alkaline or neutral conditions on ring A, B, C, or D. The substrate can be the arborescent tree itself, where AD Chen Shang The substituent of is hydrogen atom. In addition, the matrix can also be a camptothecin compound with a non- 氲 substituted * that can be reduced under age or neutral conditions. The structure (formula) shown below and all of the diagram 1 The structure (formula) represents any and all of the camptothecin compound isomers having the structure shown. For example, it represents the possible different configuration of the camptothecin compound E ring at the 20-position to generate the camptothecin compound 20 (S ) And 20 (R) two enantiomers. The scope of the present invention also includes all isomers due to the structure and / or position of the R substituent. (Please read the notes to the back # ^ ¾ wood page)

線- 經濟部中央櫺準历员工消费合作社印32. “還原” (“reduction”) 一詞以其廣化學意義來 用,意為電子從還原劑轉移到基質的任何反應。可被還原 的取代基為電子可從還原劑上或從喜樹鹼骨架構造的其他 部份轉移到該取代基上之取代基。 可被還原的取代基(R)包括硝基,氰基,《氮基,烯 基,炔基,甲醛基.齒素基Ul, Br, I, Π ,亞硝基等 。較適當者為具有2-10個硝原子的烯基,炔基和醛基。上 述例子僳只為説明而提者,必須了解的是,可在中性或驗 本紙張尺度边用中Η Η家榣準(CN5)>M規格(210X297公;Ϊ) 5 199161 Λ (i Π 6 經濟部屮央梂準局员工消仲合作社印^ 五、發明説明() 性條件下用已知的還原方法予以還原的任何取代基皆可為 本發明程序喜樹鹺基質上的取代基。當然,喜樹鹺基質上 也可以有一値以上的取代基(R)。取代基的數目較適當的 為一,但也可以為兩値,三個或更多艏,只決定於所欲喜 樹齡基質的可取得性。 喜樹鹼基質也可以含有在還原步驟中不反應的其他取 代基。這種非反應性取代基的例子包括烷基,羥烷基,烷 胺基.胺基,胺基二烷基,烷基醚等。較適當的非反應基 為具有多達10個磺原子,較適當者多逹6個磺原子者。特 別適當的非反應性基為次甲基二氣基(-0CH20-)和次乙基 二氧基(-0CHaCH20-),皆占住喜樹鹺基質上的兩個位置, 典型者是在喜樹鹾構造A-環上的兩個位置。在具有次甲基 二氧基或次乙基二氧基時,可還原性取代基R可以存在於 喜樹鹼骨架結構上剩餘可用取代位置上的一値或多個位置 之上。例如,典型的基質包括9-胺基-10,11-次甲基二氣 基喜樹龄,12-硝基-10,11-次甲基二氣基喜樹鹼,7-L-u 烷基-9-硝基-10, 11-次甲基二氣基喜樹鹼以及相對應的1〇 ,11-次乙基二氣基喜樹鹼等化合物。次甲基二氣基喜樹鹼 和次乙基二氧基喜樹鹸的9-硝基和12-硝基衍生物可用硝 酸/硫酸以傳統硝化方法將次甲基二氯基喜樹鹺或次乙基 二氧基喜樹鹼硝化而製得。 於本發明程序中,含取代基的喜樹鹼先在鹼性條件下 水解而得到E琛被水解成相對應的羧酸根和羥基的含取代 基羧酸鹽。該水解反應較適當者是在水溶液中用適當的氫 (請先閲請背而之注意事項#填筠木瓦、 本紙5fc尺度遑用中明Η家楳準(CNS)T4規格(210父297公龙) 6 199161 Λ (ί η 6 五、發明説明() 氧化物SI進行。較適當的氩氣化物飴為金靥氫氣化物,其 中的金靥離子為具有1-3價者,更適當者為鹸金屬和齡土 金屬之氫氧化物,例如氫氧化鈉,氫氣化鋰,氫氧化鉀, 氫氯化鈣,氫氧化鎂等,不過,tfc可以用三價金屬氫氧化 物。氫氣化銨和有機氫氧化物,例如,氫氧化四烷基銨類 (H為NR4,此處R為烷基或H)也適用於該水解反應 。該水解反應傜在下面的圖解1中表為“反應1”者,其 中Η為金屬離子或銨離子。 於圖解1中,還原性取代基R要了解是在環A-D中的 任何一傾上,旦是在各環的任何可用之位置上者。例如, 在Α環上的一個取代基可以出現於9, 10, 11或12等位置 的任何一個上面。在B環上的取代基則通常是在7-位置上 該氫氧化物絵通常是以與喜樹鹼基質呈相等的化學計 算比例使用的。不過,比化學計算tb例稍高或稍低的鹼用 量顯然地在水解反應中也有效用。 .1 閲 背 而 之 注 意 項 m % 本 裝 線Line-Printed by the Ministry of Economic Affairs, Central Federation of Employee Consumer Cooperatives 32. The term "reduction" is used in its broad chemical sense, meaning any reaction in which electrons are transferred from the reducing agent to the substrate. A substituent that can be reduced is one in which electrons can be transferred from the reducing agent or from other parts of the camptothecin skeleton structure to the substituent. The substituents (R) that can be reduced include nitro, cyano, nitro, alkenyl, alkynyl, formaldehyde, halogen, Ul, Br, I, Π, nitroso, etc. More suitable are alkenyl, alkynyl and aldehyde groups having 2 to 10 nitrile atoms. The above example is only for illustration. It must be understood that it can be used in the neutral or sample paper size. Η Η 家 榣 准 (CN5) > M specifications (210X297 public; Ϊ) 5 199161 Λ (i Π 6 Printed by the Employee Consumers ’Cooperative of the Central Bureau of Economic Affairs of the Ministry of Economic Affairs ^ V. Description of the invention () Any substituents that can be reduced by known reduction methods under the conditions of the invention can be the substituents on the substrate of the camphor tree of the invention program Of course, there can be more than one substituent (R) on the substrate of Hibiscus falcon. The number of substituents is more suitably one, but it can also be two, three or more bows, depending on the desire Availability of tree-age substrates. Camptothecin substrates may also contain other substituents that do not react during the reduction step. Examples of such non-reactive substituents include alkyl groups, hydroxyalkyl groups, alkylamino groups, and amine groups. Amino dialkyls, alkyl ethers, etc. A more suitable non-reactive group is one with up to 10 sulfonic atoms, and a more suitable one has 6 more sulfon atoms. A particularly suitable non-reactive group is methine digas Group (-0CH20-) and hypoethyldioxy (-0CHaCH20-), both occupying the camphor tree substrate The typical positions are two positions on the A-ring of camptothecin. In the case of methine dioxy or ethylidene dioxy, the reducible substituent R may exist in the camptothecin skeleton Above one or more positions of the remaining available substitution positions in the structure. For example, a typical substrate includes 9-amino-10, 11-methine diamino-yl camptothecin, 12-nitro-10, 11 -Methylenediaminoyl camptothecin, 7-Lu alkyl-9-nitro-10, 11-methylenedioxycamptothecin and the corresponding 1〇, 11-ethylidene diamino Camptothecin and other compounds. The 9-nitro and 12-nitro derivatives of methine diamino-camptothecin and hypoethyldioxycamptothecin can be used nitric acid / sulfuric acid in the traditional nitrification method It is prepared by nitration of chlorocamptothecin or hypoethyldioxycamptothecin. In the procedure of the present invention, the camptothecin containing substituents is first hydrolyzed under alkaline conditions to obtain Echen which is hydrolyzed to the corresponding Carboxylate and hydroxyl-containing carboxylates with substituents. The more appropriate hydrolysis reaction is to use appropriate hydrogen in aqueous solution (please read the back and forth precautions #filling the wooden shingle, this paper 5fc scale for use Zhongming Η family tree standard (CNS) T4 specification (210 father 297 male dragon) 6 199161 Λ (ί η 6 V. Description of the invention) Oxygen SI. The more suitable argon gas compound is gold tungsten hydrogen compound, of which The gold halide ions are those with 1-3 valences, and more suitable are hydroxides of metal and clay, such as sodium hydroxide, lithium hydroxide, potassium hydroxide, calcium hydrochloride, magnesium hydroxide, etc. However, tfc can use trivalent metal hydroxide. Hydrogenated ammonium and organic hydroxides, for example, tetraalkylammonium hydroxide (H is NR4, where R is alkyl or H) is also suitable for the hydrolysis reaction The hydrolysis reaction is shown as "Reaction 1" in Scheme 1 below, where H is a metal ion or an ammonium ion. In Scheme 1, it should be understood that the reducing substituent R is on any one of the rings A-D, once it is on any available position of each ring. For example, a substituent on the A ring may appear at any one of positions 9, 10, 11, or 12. The substituent on the ring B is usually at the 7-position. The hydroxide is usually used in a stoichiometric ratio equal to the camptothecin matrix. However, a slightly higher or lower base usage than the stoichiometric tb case is obviously also effective in the hydrolysis reaction. .1 Read back attention items m% of the installed line

經濟部中央梂準局员工消#合作社印M 本紙張尺度逍用中Η Η家標苹(CNS) 規格(2】(ϊχ297公龙) 7 199161 A 6 η 6 五、發明説明() 反應1Ministry of Economic Affairs, Central Bureau of Standardization, Employee Consumers, #Cooperatives, Printed M, The paper standard is used in the middle of the paper (CNS) specifications (2) (ϊχ297 male dragon) 7 199161 A 6 η 6 V. Description of invention () Reaction 1

還原reduction

經濟部中央榀準局Μ工消f合作社印製 酸化Printed by the Central Bureau of Economic Affairs of the Ministry of Economic Affairs, Mgongxiao Cooperative Society

本紙張尺度逍用中8 8家楳準卬吣)〒4規格(2丨0父297公;《;) 8The size of this paper is easy to use 8 8 楳 quasi 听 吣) 〒 4 specifications (2 father 0 father 297 ;;;) 8

五、發明説明() 接箸將具有可還原性取代基的該羧酸鹽予以還原而形 成己還原羧酸鹽。該遝原反應必須在中性或鹼性(p Η > 7 · 〇)筷件下進行使得已被水解的内酯不會再形成内酯Ε環 。還原反應可在中性或龄性水条介質,或有機溶劑等不會 干擾該還原反應且該羧酸鹽可實質地溶解在其中的介質中 進行。方便的有機溶劑為含質子溶劑,例如C, - 4低级醇類 ,主要為甲醇,乙醇,丙醇和丁醇。非質子性有機溶劑, 例如二甲基甲鏗胺(DMF)也可以用。 經濟部屮央標準局A工消赀合作社印3i 可以實施的還原反應包括氫化反應,用1為氫源者, 例如,將硝基還原成胺,將細還原成烷,將氰基還原成胺 基甲基,將鹵素還原成氫等,可在醇溶劑中,用適當的氫 化觸媒進行。各種催化氫化反應的氫化觸媒皆為熟知者且 皆可用於本發明的還原反應中(參閲Η. 0. House,Modern Synthetic Reactions (現代合成反應),2nd ed.,W. A. Benjamin, Inc., Menlo Park, (A, 1972).,其例子包括 镯媒金屬,例如Pt, Pd,Ni等,可適意地披在擔體,如炭 等之上。典型者,該羧酸鹽係溶解於絶對酒精中並於氫化 觸媒作用下進行氫化直到氫化反應(還原反應)實質地完 全為止。 還原反應也可以在水性或醇/水介質中進行。例如, 硝基喜樹鹼,如3-硝基喜樹鹼可以在乙醇/水溶劑中用Fe S04-NH* 0H方法予以順利地還原成相應的胺基羧酸鹽(參 閲I. Smith and J. W. Cpie, Org. Synth. Collect Vol. 3, ed. E. C. Horning, John Wiley and Sons,New York 9 本紙張尺度边用中a Η家橒準(CNS) 規ίΜ210χ297公*) Λ ft η () 99l6i 五、發明説明( ,N. Y., 1955, p. 56) 〇 間 背 而 之 注 意 事 項 填 % 木 rw 總括地説,可在鹼性或中性介質中進行的住何傳統還 原反應都可用為本發明的還原反應。適用的還原反應不僅 包括上面所述的氳化反應( Ha)和FeS04-NH40H方法,而 且也包括電化學還原反應,以及用阱或琛己烯作為氫源配 合金屬觸媒,如Pd或Pt等的還原反應。 己還原的羧酸鹽可以用傳統結晶法或層析分離法予以 分離出來。然後將分離出來已還原的羧酸鹽與酸接觸,典 型者與水条酸溶液接觸而再形成喜樹鹼化合物的内酯E琛 ,如圖解1中所示者。另外,也可以在含有己還原羧酸鹽 的反應介質中添加酸直接予以酸化以再形成E環。具有売 整内酯E環的己還原喜樹齡化合物比其羧酸鹽實質地較不 溶於水而可以用簡單的過濾和/或用傳統有機溶劑,如氛 仿,二氣甲烷,甲苯等萃取予以方便地分離出來。 經濟部中央櫺準局Μ工消伢合作杜印製 該酸化步驟可用礦物酸或有機酸來進行。適用的礦物 酸包括鹽酸,溴酸,硫酸,磷酸等。適當的有機酸包括醋 酸,對甲苯磺酸,三氟醋酸,草酸,酒石酸等,酸通常是 以稀溶液,較適當者,0.1-1.0克分子/升濃度,添加進 去,不過,酸的濃度並非關鍵因素。 本發明程序可以經由將喜樹鹸轉化成水溶性羧酸鹽, 將該羧酸鹽還原而後再内酯化E琛而再形成喜樹齡骨架結 構等程序而得以在喜樹鹼和喜樹鹼類似物上進行高産率的 還原反應。本發明方法可導致喜樹鹼類似物製備的産率增 加及其合成步驟的彈性加多等好處。 本紙張尺度逍用中a Η家榣毕(CNS) Τ4規格(210X297公;it) Λ () Η 6 199161 五、發明説明() (請先閲讀背而之注意事'項#碼寫本一 本發明程序可以用來合成20(RS)-喜樹20(S)_喜 樹齡或2C(R)-喜樹鹹等衍生物或(R)和(S)對映異構物混合 物。在對其對映異構物的混合物進行反應時,羧酸鹽的形 成,還原反應和内酯環的再形成等皆可在該混合物上進行 。所得到的已還原(R)化合物和(S)化合物之混合物可以用 已知的拆離程序方便地拆離成値別的對映異構物。例如, 20(RS)_喜樹鹼衍生物可以經由與適當的旋光性胺,例如 ,R-( + )-a-甲基苯甲胺或S-(-)-a-甲基苯甲胺等依據美 國專利申請序號07/511,953中所掲示的方法進行反應形 成相應的非對映異構性醛胺類而予以拆離開來;此處,該 專利申請案列為本發明之參考文獻。在分離該非對映異構 性醛胺後,將該醛胺用酸處理即可再形成完整的喜樹鎊環 構造。 本發明的其他特性可經由下面實施例的說明而更明白 ,但這些實施例係供本發明解詋之用而無意用以限制本發 明。於下面的實施例中,有實際付諸操作的實施例係以過 去式書寫,而推斷地可實施之實施例則以現在式書寫。 奮掄例 經濟部屮央梂準局A工消赀合作社印製 音旃例1——10-胺某-20 (RS)-葚榭鹼用FftSn,-ΝΗ,ΠΗ法 m m 將10-硝基-20(RS)-喜樹鹼( 200毫克,0.5毫克分子 )在90% MeOH (50毫开)和0.1 N HaOH (5毫升)中的懸 浮液於氮氣下在50-60°C加熱一小時。然後,將大部份的 MeOH減壓蒸發掉,所得褐色固體再溶解於水(10毫升)中 本紙張尺度逍用中8 B家標毕(CN5) TM規格(210x297公Λ)5. Description of the invention () Then, the carboxylic acid salt having a reducible substituent is reduced to form a reduced carboxylic acid salt. The proton reaction must be carried out under neutral or basic (p Η > 7 · 〇) chopsticks so that the lactone that has been hydrolyzed will no longer form the lactone E ring. The reduction reaction can be carried out in a medium such as a neutral or aged water bar medium, or an organic solvent which does not interfere with the reduction reaction and the carboxylate can be substantially dissolved therein. Convenient organic solvents are protic solvents, such as C, -4 lower alcohols, mainly methanol, ethanol, propanol and butanol. Aprotic organic solvents, such as dimethylmethineamine (DMF) can also be used. The Ministry of Economic Affairs, Bureau of Standards, A Industrial Consumer Affairs Cooperative, printed 3i. The reduction reactions that can be carried out include hydrogenation, using 1 as the hydrogen source, for example, reducing nitro to amine, reducing fine to alkane, and reducing cyano to amine. The methyl group, reducing the halogen to hydrogen, etc., can be carried out in an alcohol solvent with an appropriate hydrogenation catalyst. Various hydrogenation catalysts for catalytic hydrogenation reactions are well-known and can be used in the reduction reaction of the present invention (see Η. 0. House, Modern Synthetic Reactions (modern synthesis reaction), 2nd ed., WA Benjamin, Inc., Menlo Park, (A, 1972)., Examples of which include bracelet metals, such as Pt, Pd, Ni, etc., can be suitably coated on supports such as charcoal, etc. Typically, the carboxylate is dissolved in absolute Hydrogenation in alcohol and under the action of a hydrogenation catalyst until the hydrogenation reaction (reduction reaction) is substantially complete. The reduction reaction can also be performed in an aqueous or alcohol / water medium. For example, nitrocamptothecin, such as 3-nitro Camptothecin can be successfully reduced to the corresponding aminocarboxylate in Fe / S04-NH * 0H in ethanol / water solvent (see I. Smith and JW Cpie, Org. Synth. Collect Vol. 3, ed . EC Horning, John Wiley and Sons, New York 9 This paper is used in the marginal standard a Η 家 橒 准 (CNS) regulation ί210210297 *) Λ ft η () 99l6i V. Description of the invention (, NY, 1955, p. 56 ) 〇Contrary precautions should be filled with% wood rw. Both traditional and traditional reduction reactions carried out in neutral or neutral media can be used as the reduction reaction of the present invention. Suitable reduction reactions include not only the above-mentioned Raization (Ha) and FeS04-NH40H methods, but also electrochemical reduction. Reaction, and the use of traps or hexene as a hydrogen source to cooperate with metal catalysts, such as Pd or Pt reduction reaction. The reduced carboxylic acid salt can be separated by traditional crystallization method or chromatographic separation method. Then the separation The reduced carboxylate is contacted with an acid, which is typically contacted with a water stripe acid solution to form the lactone Echen, which is a camptothecin compound, as shown in Figure 1. In addition, it may also contain a reduced carboxylate The acid is added directly to the reaction medium to acidify it to form the E ring. The reduced camptothecin compound with the E ring of the lactone is substantially less soluble in water than its carboxylate and can be filtered with simple and / or traditional Organic solvents, such as chloroform, methane, toluene, etc., can be easily separated by extraction. The central bureau of the Ministry of Economic Affairs, Mgong Consumer, cooperated to produce the acidification step. This acidification step can be performed with mineral or organic acids Suitable mineral acids include hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. Suitable organic acids include acetic acid, p-toluenesulfonic acid, trifluoroacetic acid, oxalic acid, tartaric acid, etc. The acid is usually a dilute solution, which is more appropriate, 0.1-1.0 Molar / liter concentration, added, but the acid concentration is not a critical factor. The process of the present invention can be converted into water-soluble carboxylates by camptotheca cucurbita, the carboxylates are reduced and then lactonized. The formation of camptothecin age skeleton structure and other procedures enables high-yield reduction reactions on camptothecin and camptothecin analogs. The method of the present invention can lead to increased yields of camptothecin analogs and increased flexibility of the synthesis steps. The size of this paper is easy to use a Η 家 榣 毕 (CNS) Τ4 specifications (210X297 public; it) Λ () Η 6 199161 V. Description of invention () (please read the back-end considerations' item # code write a copy first The inventive program can be used to synthesize derivatives such as 20 (RS) -camptotheca 20 (S) _camptothecin or 2C (R) -camptotheca or mixtures of (R) and (S) enantiomers. When the mixture of enantiomers is reacted, the formation of carboxylate, the reduction reaction and the reformation of lactone ring can be carried out on the mixture. The resulting reduced (R) compound and (S) compound The mixture can be conveniently separated into other enantiomers using known separation procedures. For example, 20 (RS) -camptothecin derivatives can be passed through an appropriate optically active amine, for example, R- (+ ) -a-methylbenzylamine or S-(-)-a-methylbenzylamine, etc. are reacted according to the method shown in US Patent Application Serial No. 07 / 511,953 to form the corresponding diastereomeric aldamine It is removed from the category; here, the patent application is listed as a reference of the present invention. After separating the diastereoisomeric aldol, the aldol can be treated with acid A complete camptotheca pound ring structure is formed. Other features of the present invention can be more clearly understood through the description of the following examples, but these examples are for the purpose of explaining the present invention and are not intended to limit the present invention. In the following examples In the past, some practical examples were written in the past tense, and the presumably implementable examples were written in the present tense. Fen Lian Fen The Ministry of Economic Affairs, Central Bureau of Industry and Commerce A Co-operative Cooperative Society printed audio examples. 1——10-Amino-20 (RS) -Panthrene base FftSn, -ΝΗ, ΠΗ method mm 10-Nitro-20 (RS) -camptothecin (200 mg, 0.5 mg molecule) in 90% The suspension in MeOH (50 mK) and 0.1 N HaOH (5 mL) was heated under nitrogen at 50-60 ° C for one hour. Then, most of the MeOH was evaporated under reduced pressure, and the resulting brown solid was redissolved in Water (10ml) medium and small paper size 8 B home standard (CN5) TM specification (210x297 g)

五、發明説明 ηηV. Description of Invention ηη

A (i Η G 經濟部中央榀準扃A工消奸合作社印製 並用G . 45微米濾膜過濾以除去任何不溶性物質。將水減壓 脱除而得到10-硝基-2Q(RS)-喜樹鹼的鈉鹽(213¾克,産 率 97% )。 將10-硝基-20(RS)-喜樹齡納鹽(200¾克,(1.46¾克 分子)溶解於熱的50%乙醇水溶液(20毫升)中,再加到 FeSCK · 7H2〇 (2.0克,7‘2毫克分子)/沸水(20毫升) 溶液中。慢慢地將氫氧化莰(3毫升)加到該沸騰溶液内 。將該反應混合物趁熱用Cel ite (矽藻土商品名)墊過濾 並用熱水(10毫升)洗滌。將黃光螢光性濾液用稀HC1中 和後,置於蒸汽浴上加熱15分鐘·。然後將濾液冷卻,再用 CHC13萃取(5X100毫升)。將氣仿萃取液脱水(Na2S〇4) 後減壓蒸發得到纯的10-胺基-20 (RS)-喜樹鹼(184毫克, 100% )。此樣品的光譜性質與標準樣品的光譜性質相同 10-胺某-20<RS)-寞樹龄.用催化蒱脖洁韌 備 將實施例製備的1Q-硝基-20(RS)-喜樹鹼鈉鹽(11.0 毫克,0.0 25毫克分子)與10% Pd/C (6.0毫克)在無水 EtOH (10毫升)中的混合物接受1 atm Ha處理1小時。之 後,用celite過濾脱除觸媒。用無水EtOH (50毫升)充分 地洗滌濾塊以取得其餘被吸附住的産物。將濾液用稀HC1 酸化後,在水浴上溫熱1G分鐘再用CHC13萃取(5X25毫升 )。然後,將脱水(Na2S〇4)後的氯仿萃取液減壓蒸發而 得到10-胺基-20(RS)-喜樹鹼(7.0毫克,76%)。此搛品 (讣洗閲1>||背而之注悲卞項外堺寫本π) 裝. 本紙法尺度边用中a Η家樣準(CNS) ΤΊ規格(210x297公龙) 12 五、發"/]説明() 的光譜性質與標準樣品的光譜性質相同。 J〇ttJ2UL·——胺甚-喜樹鹼.用 Fαη,-ΝΗ,ΠΗ方 法.製備 將9_硝基-20 (RS)-喜樹龄( 2 0 0¾克,0.5毫克分子) 在90%MeOH (50毫升)和0.1 N NaOH (5毫升)中的懸浮 液於氮氣下在5 0 - 6 0°C加熱一小時。之後,將大部份的 MeOH減壓蒸掉,所得褐色固體再溶解於水中(1〇毫升)並 用0 · 45微米濾膜過濾以脱除任何不溶性物質。然後,將溶 劑減壓脱除得到9-硝基-2Q(RS)-喜樹齡鈉鹽(215毫克, 98% ) 0 經濟部屮央51準扃员工消合作社印?4 將9-硝基-20(RS)-喜樹鹼鈉鹽(213毫克,0.51毫克 分子)溶解於熱的5G%乙醇水溶液(2Q毫升)後加到FeS(K •7H2 0(2.0克,7.2毫克分子)/沸水(20毫升)溶液中 。慢慢地將氫氧化銨(3毫升)加到該沸騰溶液中。然後 將反應混合物趁熱用celite濾墊過濾並用熱水(1Q毫升) 洗滌。濾液用稀HC1予以酸化後置於蒸汽浴上加熱15分鐘 。接著,濾出黃色沈澱物並予以乾燥(137毫克)。濾液 用CHC13萃取(5X50毫升)。將脱水後(NaaS04)的氡仿 萃取液減壓蒸發即得純的9-胺基-2Q(RS)-喜樹齡。合併純 産物的重量為146.0毫克(81%)。此樣品的光譜性質與 標準樣品的光譜性質相同。 g旃例4——9-胺某-?.0 (RD-寞榭鹾.用催 卜.蒱鹿法靱描A (i Η G Printed by the Central Ministry of Economic Affairs, A Gong Xiaoyao Cooperative and filtered with a G. 45 micron filter membrane to remove any insoluble materials. The water is removed under reduced pressure to obtain 10-nitro-2Q (RS)- Camptothecin sodium salt (213¾ g, yield 97%). Dissolve 10-nitro-20 (RS) -camptothecin sodium salt (200¾ g, (1.46¾ mol) in hot 50% ethanol aqueous solution ( 20 ml), then add to FeSCK · 7H2〇 (2.0 g, 7'2 mg) / boiling water (20 ml) solution. Slowly add camphor hydroxide (3 ml) to the boiling solution. The reaction mixture was filtered with Cel ite (diatomite trade name) pad while hot and washed with hot water (10 ml). After neutralizing the yellow fluorescent filtrate with dilute HC1, it was placed on a steam bath and heated for 15 minutes. The filtrate was cooled, and then extracted with CHC13 (5X100 mL). The gaseous extract was dehydrated (Na2S〇4) and evaporated under reduced pressure to obtain pure 10-amino-20 (RS) -camptothecin (184 mg, 100%) The spectral properties of this sample are the same as those of the standard sample. 10-Amino-20 < RS) -Lonely Tree Age. Prepared by the examples A mixture of 1Q-nitro-20 (RS) -camptothecin sodium salt (11.0 mg, 0.0 25 mg molecule) and 10% Pd / C (6.0 mg) in anhydrous EtOH (10 ml) was treated with 1 atm Ha 1 After that, the catalyst was removed by filtration with celite. The filter cake was washed thoroughly with anhydrous EtOH (50 mL) to obtain the remaining adsorbed product. After the filtrate was acidified with dilute HC1, it was warmed on a water bath for 1G minutes before reuse CHC13 extraction (5 × 25 mL). Then, the dehydrated (Na 2 SO 4) chloroform extract was evaporated under reduced pressure to obtain 10-amino-20 (RS) -camptothecin (7.0 mg, 76%). (讣 洗 读 1> || Backward note tragic Bian Xiangwai Sai writing π) installed. This paper is used in the standard scale of a Η family sample standard (CNS) ΤΊ specification (210x297 male dragon) 12 V. issued " / ] Description () The spectral properties are the same as those of the standard sample. J〇ttJ2UL · ——Amine even-camptothecin. Using Fαη, -ΝΗ, ΠΗ method. Preparation of 9_nitro-20 (RS)-喜The suspension of the tree age (2 0 0¾ g, 0.5 mg molecule) in 90% MeOH (50 ml) and 0.1 N NaOH (5 ml) was heated under nitrogen at 50-60 ° C for one hour. After that, Most The MeOH was distilled off under reduced pressure, and the resulting brown solid was redissolved in water (10 mL) and filtered through a 0.45 micron filter membrane to remove any insoluble materials. Then, the solvent was removed under reduced pressure to obtain 9-nitro-2Q ( RS) -Kizuki Ling Sodium Salt (215 mg, 98%) 0 Ministry of Economic Affairs, Yanyang 51 quasi-employee consumer cooperatives printed? 4 Dissolve 9-nitro-20 (RS) -camptothecin sodium salt (213 mg, 0.51 mg molecule) in hot 5G% ethanol aqueous solution (2Q ml) and add to FeS (K • 7H2 0 (2.0 g, 7.2 mg) / boiling water (20 mL) solution. Slowly add ammonium hydroxide (3 mL) to the boiling solution. The reaction mixture was then filtered with a celite filter pad while hot and washed with hot water (1Q mL) The filtrate was acidified with dilute HC1 and placed on a steam bath for 15 minutes. Next, the yellow precipitate was filtered off and dried (137 mg). The filtrate was extracted with CHC13 (5X50 mL). The dehydrated (NaaS04) radon was used The extract is evaporated under reduced pressure to obtain pure 9-amino-2Q (RS) -Camellia. The combined pure product weighs 146.0 mg (81%). The spectral properties of this sample are the same as those of the standard sample. G 旃Example 4-9-Amino-?. 0 (RD-lone pavilion. Use reminder. Kulu method description

將實施例3所得9-硝基-20 (RS)-喜樹鹼鈉鹽(20 ·〇毫 克,0.4S毫克分子)與l〇%Pd/C (1G.0毫克)在無水EtOH 本紙張尺度边用中a s家炫爭(CNS) τ4規格(21〇x297公龙) 丨於 η 6 (5毫升)中的混合物接受1 atn. Ha處理18小時。之後 水 ,用celite濾除觸媒。用無'ItOH (50毫升)充分洗路該濾 塊以取得其他被吸附的産物。濾液用稀HC1酸化後,置於 水浴上溫熱10分鐘。濾出掲色9-硝基-2 0(RS)-喜樹驗沈澱 物(6.2毫克)。濾液用CHC13萃取(5X20毫升)。將已 脱水(HasS(]«)氛仿萃取液減壓蒸發得到額外量的9-胺基 -20(1?3)-喜樹齡(3.6毫克)。該産物用總産率為9.8毫克 (58%)。此樣品的光譜性質與標準樣品的光譜性質相同The 9-nitro-20 (RS) -camptothecin sodium salt (20.0 mg, 0.4 S mg molecule) obtained in Example 3 and 10% Pd / C (1G.0 mg) on anhydrous EtOH paper scale While using CNS τ4 specifications (21〇x297 male dragon) 丨 in η 6 (5 ml) mixture received 1 atn. Ha treatment for 18 hours. After the water, use celite to filter out the catalyst. Wash the filter thoroughly with No'ItOH (50 mL) to obtain other adsorbed products. After the filtrate was acidified with dilute HC1, it was placed on a water bath and warmed for 10 minutes. The 9-nitro-2 0 (RS) -camptothecae precipitate (6.2 mg) was filtered out. The filtrate was extracted with CHC13 (5 × 20 ml). The dehydrated (HasS () «) acetone extract was evaporated under reduced pressure to obtain an additional amount of 9-amino-20 (1? 3) -camptotheca age (3.6 mg). The total yield of this product was 9.8 mg (58 %). The spectral properties of this sample are the same as those of the standard sample

審旆例FS 利用類似實施例1和2所述程序,可以將11--硝基-20(RS)-, 9-硝基-20(R)-, 9-硝基-20(S)-, 10-硝基-20 (R) -, 10--硝基-20(S)-, 11-硝基-20(R)-,和 11-硝基-2 0(S)-等喜樹鹼化合物用FeSChHOH法或催化還原法還 原成相應的11-胺基-20(RS)-, 9-胺基-20(R)-,9-胺基-20 (S) -, 10-胺基-20(R)-, 10-胺基-20(S)-, 11-硝基-20(R) 和11-胺基-20(S)-等喜樹鹼衍生物。 啻旆例β 經濟部屮央楳準局κχ工消坨合作社印3i (請先閲讀背而之注意事項再填寫木頁) 類似實施例1之程序,將9-硝基-10,11-次甲基二氧 基-20 (S)-喜樹龄於含有NaOH的甲醇内之懸浮液加熱而得 到9-硝基-10, 11-次甲基二氣基-20 (S)-喜樹鹼鈉鹽。然後 將該鈉鹽溶解於熱的50%乙醇水溶液中,再加到FeSO〆 7Ha 0/沸水溶液内。以實施例1所述方式將氮氧化銨加到 該沸騰溶液中。過濾後,以類同實施例1所述者予以酸化 本紙張尺度边用中a B家標準(CNS)甲4規格(210x297公*) 199161 Λ (i Β6 五、發明説明( 和處理即得到9-胺基-10,11-次甲基二氣基-20 (S)-喜樹齡 〇 顯然地.依據上面的説明可以對本發明産生多的修飾 與變動。因此,要了解的是,在後附申請專利範圍所逑範 圍内,本發明也可以用有別於上面待別說明之方式操作而 成。 -請 先 閲 讀 背 而 之 注 奇 苯· 項 堝. % 裝 η 線 經濟部屮央橾準局Α工消费合作杜印製 本紙張尺度边用肀BB家樣準(CNS)T4規格(210x297公*)Examining Example FS Using procedures similar to those described in Examples 1 and 2, 11-nitro-20 (RS)-, 9-nitro-20 (R)-, 9-nitro-20 (S)- , 10-nitro-20 (R)-, 10-nitro-20 (S)-, 11-nitro-20 (R)-, and 11-nitro-2 0 (S)- The alkali compound is reduced to the corresponding 11-amino-20 (RS)-, 9-amino-20 (R)-, 9-amino-20 (S)-, 10-amino by FeSChHOH method or catalytic reduction method Camptothecin derivatives such as -20 (R)-, 10-amino-20 (S)-, 11-nitro-20 (R) and 11-amino-20 (S)-. Example β β3i printed by the Cooperative Society of the Ministry of Economic Affairs, 揮 阳 楳 Bureau of Economic Affairs (please read the precautions before filling in the wooden page) Similar to the procedure of Example 1, the 9-nitro-10,11-times Methyldioxy-20 (S) -camptothecin suspension in NaOH-containing methanol is heated to obtain 9-nitro-10,11-methinediamino-20 (S) -camptothecin Sodium salt. Then dissolve the sodium salt in a hot 50% ethanol aqueous solution and add it to FeSO〆 7Ha 0 / boiling aqueous solution. Ammonium oxynitride was added to the boiling solution in the manner described in Example 1. After filtration, it is acidified by the same method as described in Example 1 in this paper. The paper is used in a standard (CNS) A4 specification (210x297 g *) 199161 Λ (i Β6 V. Description of the invention (and treatment will get 9 -Amino-10,11-methinediamino-20 (S) -Camellia age. Obviously, many modifications and changes can be made to the present invention according to the above description. Therefore, it is understood that Within the scope of the patent application, the present invention can also be operated in a way different from the above-mentioned to be explained separately.-Please read the note to the contrary. Benzene. Item pot.% 装 η Line Ministry of Economic Affairs Bureau A, Consumer, and Consumer Cooperation Co., Ltd. Printed paper with a standard BB BB standard (CNS) T4 specification (210x297 g *)

Claims (1)

A7 B7 C7 D7 六、申請專利範圍 第δΟ 10925 5號專利再審査案申請專利範圍修正本 修正日期:8 1年1 2月 1 - 一種用以製備還原喜樹險之方法,其包括下列步驟: ⑴在鹼性條件下水解一具有下面所示構造的喜樹齡化合 物之内酯Ε環 (請先閲讀背面之注意事項再塡寫本頁)A7 B7 C7 D7 VI. Application for Patent Scope No. δΟ 10925 No. 5 Patent Reexamination Case Application for Amendment of Patent Scope Amendment Date: 8 1 year 1 February 1-A method for preparing restoration of hiki tree insurance, which includes the following steps: (1) Hydrolyze a lactone E ring of a camptothecin compound with the structure shown below under alkaline conditions (please read the precautions on the back before writing this page) (其中A,B,C,及D環中至少有一者其上含有至少一 個可在鹼性或中性條件下被還原的取代基R,該取代 基R傜選自由硝基,氣基,C2M。烯基,C*-1D炔基, 鹵素基,亞硝基和甲醯基所組成之群中), 為 以形成一具有下面所示化學式之水溶性經取代的羧酸 鹽(Wherein at least one of rings A, B, C, and D contains at least one substituent R which can be reduced under basic or neutral conditions, the substituent R is selected from the group consisting of nitro, gas, C2M .Alkenyl, C * -1D alkynyl, halo, nitroso, and formyl group), in order to form a water-soluble substituted carboxylate with the chemical formula shown below •裝. 訂. 4· 烴濟部中央標準曷8工消费合作社印製 性 中及 或 ; 性鹽 中鹼酸 其在羧 ⑵ 子 離 陽 的 原 還 一 成 形 而 R 基 代 取 該 原 還 中 質 酯 内 該 使 而 觸 接 酸 一 酯 與内 鹽該 酸使 羧能 的一 原傜 還酸 該該 令 , 成 , 形酸 再機 環有 或 酸 礦 之 成 形 再 環 本紙張又度適用中國國家標準(CNS)甲4规格(210 X 297公釐) 1 199161 Λ7 B7 Cl D7 '申請專利範圍 其中該有機酸實質上偽由醋酸、對甲苯磺酸、三氣醋 經濟部中央標準局貝工消費合作社印製 酸、草酸與酒石酸所組成。 2 _如申請專利範圍第1項之方法,其中 參價的金屬陽離子。 3 .如申請專利範圍第1項之方法,其中 金屬陽離子,四-Ci-,-烷基銨離子或 4.如申請專利範圍第1項之方法,其中 5 .如申請專利範圍第4項之方法,其中 酸,硫酸或磷酸。 6 .如申謓專利範圍第丨項之方法,其中 A環之9,10,11或12位置上的硝基。 7 ·如申請專利範圍第1項之方法.其中 化性氫化反應。 8 .如申請專利範圍第丨項之方法,其中 使用FeS〇4-NH4〇H進行的還原反應。 9.如申請專利範圍第7項之方法,其中 應條一使用Η 2作為氫源而進行者。 1〇·如申請專利範圍第7項之方法,其中 醮係一使用肼作為氫源而進行者。 11 ·如申請專利範圍第7項之方法,其中 應偽一使用環己烯作為氫源而進行者 12.如申請專利範圍第1項之方法,其中 電化學還原反應。 Η為單價 價或 Μ為鹼金屬或鹼土 銨離子。 該酸為礦酸。 該礦酸為鹽酸,溴 該取代基為一位在 ,該還原反應俗催 ,該還原反應傜一 ,該催化性氫化反 ,該催化性氫化反 ,該催化性氫化反 Ο ,該還原反應係一 請 先 閲 讀 背 之 注 念 事 項 再 填 寫 本 頁 裝 訂 本纸張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 2• Installed. Ordered. 4. The Central Standard of the Ministry of Hydrocarbon Economics and Consumers ’Cooperatives prints neutrality or neutrality; the alkaline acid in the sexual salt is formed in the original source of the carboxyl ⑵ son from the sun, and the R group is replaced by the original source. The acid ester should be in contact with the acid monoester and the internal salt. The acid will make the carboxyl-enriched urethane regenerate the acid, and the order will be formed. The acid is re-circulated or the ore is formed. The paper is again suitable for China. National Standard (CNS) A4 specification (210 X 297 mm) 1 199161 Λ7 B7 Cl D7 'Application for patent scope in which the organic acid is essentially derived from acetic acid, p-toluenesulfonic acid, three gas vinegar Central Standards Bureau The consumer cooperatives are composed of printed acid, oxalic acid and tartaric acid. 2 _ The method as described in item 1 of the patent application, in which the valence of metal cations. 3. The method as claimed in item 1 of the patent scope, wherein the metal cation, tetra-Ci-, -alkylammonium ion or 4. The method as claimed in item 1 of the patent scope, where 5. As in the application of item 4 of the patent scope Method, where acid, sulfuric acid or phosphoric acid. 6. The method of item 丨 in the scope of the patent application, in which the nitro group at the 9, 10, 11 or 12 position of the A ring. 7. The method as in item 1 of the patent application scope. The chemical hydrogenation reaction. 8. The method as claimed in item 丨 of the patent application scope, wherein the reduction reaction using FeS〇4-NH4〇H is performed. 9. The method as claimed in item 7 of the patent application, in which the first step is to use H 2 as a hydrogen source. 10. A method as claimed in item 7 of the patent application, wherein the method is performed using hydrazine as a hydrogen source. 11. The method as claimed in item 7 of the patent application, which should be carried out using cyclohexene as a hydrogen source 12. The method as claimed in item 1 of the patent application, wherein the electrochemical reduction reaction. Η is monovalent or M is alkali metal or alkaline earth ammonium ion. The acid is mineral acid. The mineral acid is hydrochloric acid, the substituent of bromine is a single bit, the reduction reaction is urged, the reduction reaction is one, the catalytic hydrogenation is reversed, the catalytic hydrogenation is reversed, the catalytic hydrogenation is reversed, the reduction reaction system is 1. Please read the notes on the back before filling in this page. The paper size is in accordance with Chinese National Standard (CNS) Grade 4 (210 X 297 mm) 2
TW80109255A 1990-09-13 1991-11-25 Improvements process for chemical reactions on camptothecin or analogs thereof TW199161B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58239890A 1990-09-13 1990-09-13

Publications (1)

Publication Number Publication Date
TW199161B true TW199161B (en) 1993-02-01

Family

ID=51356477

Family Applications (1)

Application Number Title Priority Date Filing Date
TW80109255A TW199161B (en) 1990-09-13 1991-11-25 Improvements process for chemical reactions on camptothecin or analogs thereof

Country Status (1)

Country Link
TW (1) TW199161B (en)

Similar Documents

Publication Publication Date Title
EP0538534A1 (en) Improved process for chemical reactions on camptothecin or analogs thereof
EP0915884B1 (en) Preparation of narcotic analgesics
ES2467920T3 (en) Procedure to reduce the 6-keto group from a morphinan alkaloid to the 6-hydroxy group by hydrogenation
FR2577217A1 (en) PROCESS FOR HYDROGENATION OF ACETIC ACID
Habuš et al. Chiral bidentate ligands from the most widespread monosaccharides for enantioselective hydrogenation: diphenylphosphinites from D-glucose and D-xylose
CN113999084A (en) Synthetic preparation method of (S) - (-) -nicotine
JP5371031B2 (en) Hydride metal complex and low valent metal complex, and method using them to extract electrons from hydrogen molecule, method for hydrogenating substrate, and method for producing hydrogen from deuterium
TW199161B (en) Improvements process for chemical reactions on camptothecin or analogs thereof
JPH01193246A (en) Production of 2,3-dichloropyridine
JP2007501275A (en) Process for preparing 7-alkyl-10-hydroxy-20 (S) -camptothecin
TWI287016B (en) Process for preparing camptothecin
JP4809985B2 (en) Method for producing 3-arylpropylamine
JPH07138210A (en) Production of aminopropane derivative
JPS5951288A (en) Novel 9-camptothecin and its preparation
CN115260092B (en) Synthesis method of 2-chloronicotinamide and N-substituted derivative thereof
IE913701A1 (en) Improved process for chemical reactions on camptothecin or¹analogs thereof
CN114426516B (en) Preparation method of 2-amino-3-bromopyridine
JPS6031824B2 (en) Method for producing hydroxyphenylpiperidinyl methanol derivative
CN104039764B (en) The preparation method of octahydro-cyclopentano [c] pyrroles
US8476438B2 (en) Process for production of camptothecin derivative
JP4224144B2 (en) Process for producing N-alkylpyridinemethanamines
JPS6151595B2 (en)
JP2002506845A (en) Method for producing 4-substituted cis-cyclohexylamine
CA2261675C (en) Preparation of narcotic analgesics
JP4314602B2 (en) Process for producing optically active 3-hydroxypyrrolidine derivative